147403-65-4

Basic information

• Product Name: (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate
• Synonyms: (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate;(Z)-Methyl 2-ethoxy-1-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-1H-benzo[d]iMidazole-7-carboxylate;2-Ethoxy-1-[[2'-[(hydroxyaMino)iMinoMethyl][1,1'-biphenyl]-4-yl]Methyl]-1H-benziMidazole-7-carboxylic Acid Methyl Ester;(Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-ca;Methyl 2-ethoxy-1-((2'-(N-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole;InterMediate of Azilsartan;Methyl 2-ethoxy-1-((2'-(N-hydroxycarbaMiMidoyl)-[1,1'-biphenyl]-4-yl)Methyl)-1H-benzo[d]iMidazole-7-carboxylate;2-Ethoxy-1-｛[2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl]Methyl｝-1H-benzo[d]iMidazole-7 -carboxylic acid Methyl ester
• CAS NO: 147403-65-4
• Molecular Formula: C₂₅H₂₄N₄O₄
• Molecular Weight: 444.48246
• EINECS: 1592732-453-0
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 147403-65-4.mol
• Article Data: 19

Chemical Properties

• Melting Point: 207-209℃
• Boiling Point: 657.2±65.0 °C(Predicted)
• Appearance: /
• Density: 1.29
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 6.77±0.69(Predicted)
• CAS DataBase Reference: (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate(147403-65-4)
• EPA Substance Registry System: (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate(147403-65-4)

Safety Data

• Hazardous Substances Data: 147403-65-4(Hazardous Substances Data)

Usage

Description

(Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate is a complex organic compound characterized by its chemical structure and properties. It is a white solid, which indicates its stability and potential for use in various applications.

Uses

1. Pharmaceutical Industry:
(Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate is used as an intermediate in the synthesis of angiotensin II receptor antagonists, specifically for the development of Azilsartan (A926900) derivative. This application is due to its chemical properties that allow it to be a key component in the creation of drugs that help regulate blood pressure and treat hypertension.
2. Chemical Research and Development:
As a white solid with unique chemical properties, (Z)-Methyl 2-ethoxy-3-((2'-(N'-hydroxycarbaMiMidoyl)biphenyl-4-yl)Methyl)-3H-benzo[d] iMidazole-4-carboxylate can be used in various chemical research and development projects. Its specific properties make it a valuable compound for further exploration and potential development of new drugs or materials.
3. Drug Synthesis and Design:
The compound's structure and properties make it a potential candidate for use in drug synthesis and design, particularly in the development of new pharmaceuticals targeting specific receptors or biological pathways. Its role as an intermediate in the synthesis of angiotensin II receptor antagonists highlights its potential in this application.

Upstream product

• 139481-44-0 methyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-ethoxy-benzimidazole-7-carboxylate 
• 1403477-45-1 methyl 2-ethoxy-1-((2'-(N'-(methoxycarbonyloxy)carbamimidoyl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 

Downstream Products

• 147403-03-0 azilsartan 
• 147403-52-9 methyl 2-ethoxy-1-((2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]-imidazole-7-carboxylate 
• 863031-21-4 Azilsartan medoxomil 
• 147404-82-8 2-ethoxy-1-[[2'-[N'((ethoxycarbonyl)oxy)carbamimidoyl][1,1-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid methyl ester 
• 1403474-78-1 methyl 2-oxo-3-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate 
• 108-95-2 phenol 
• 1417576-00-1 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-((2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1’-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate 
• 1417576-01-2 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2′-(4-ethyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 1403477-44-0 methyl 2-ethoxy-1-((2'-(N'-(phenoxycarbonyloxy)carbamimidoyl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 1499167-76-8 methyl 2-ethoxy-1-((2'-(4-ethyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate 
• 1397836-49-5 1-[(2'-(N'-hydroxycarbamimidoyl)[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-1,3-benzodiazole-7-carboxylic acid 
• 1449029-77-9 (5-methyl-2-oxo-2H-1,3-dioxol-4yl)methyl 2-ethoxy-1-[(4-(2-[N-hydroxy-carbamimidoyl]phenyl)phenyl)-methyl]-1H-1,3-benzodiazole-7-carboxylate 
• 1449029-78-0 (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl 2-ethoxy-1-[(2'-{N'-[(ethoxycarbonyl)oxy]carbamimidoyl}-biphenyl-4-yl)-methyl]-1H-benzimidazole-7-carboxylate 
• 1449029-80-4 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(N'-{[(4-nitrophenoxy)carbonyl]oxy}carbamimidoyl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate 

Relevant articles and documents

Synthesis technology for continuously preparing azilsartan in micro-channel reactor

The invention discloses a synthesis technology for continuously preparing azilsartan in a micro-channel reactor. The technology comprises the following steps: (1) adding SM-1, an aqueous hydroxylaminesolution and triethylamine into anhydrous ethanol, and performing a reaction to obtain an intermediate TAK1; (2) preparing a homogeneous solution A from the TAK1, triethylamine and dioxane; (3) preparing a homogeneous solution B from solid phosgene and dioxane; (4) dissolving sodium hydroxide in water to prepare a homogeneous solution C; (5) respectively pumping the homogeneous solution A and thehomogeneous solution B into a microstructure mixer I in a micro-channel reaction device at the same time, performing mixing, and introducing the obtained mixed solution into a microstructure reactorI; (6) respectively pumping the homogeneous solution C and the effluent of the microstructure reactor I into a microstructure mixer II in the micro-channel reaction device at the same time while step(5) is carried out, performing mixing, and introducing the obtained mixed solution into a microstructure reactor II; and (7) collecting the effluent of the microstructure reactor II to obtain the product azilsartan.

A method for preparing [...]

The invention relates to an azilsartan (a hypertension treating medicine) preparation method, and belongs to the field of medicines. The method has the beneficial effects that a compound 1 serves as an initial raw material of the reaction, the azilsartan is prepared through three reaction steps of hydroxylammonium chloride addition, ethyl chloroformate acylation and cyclization hydrolysis under the alkali action, and the cyclization and hydrolysis reaction steps of the prior art are combined into one step, so that conventional 4-5 steps are reduced to three steps, and the reaction time is shortened; and the yield is increased, the content of ethyoxyl-removing impurities is greatly reduced, experimental operations are simplified, the cost is lowered, the azilsartan with high purity is obtained, the high performance liquid chromatography (HPLC) purity is more than 99.5%, and the ethyoxyl and amide-removing impurities are all less than 0.1%.

Preparation method of Azilsartan low in amide impurity content

The invention discloses a preparation method of Azilsartan low in amide impurity content. According to the preparation, in a step of preparation of an intermediate III from an intermediate II, a metalchelating agent, and a phase transfer catalyst are added. The preparation method of Azilsartan low in amide impurity content is capable of controlling influences of trace metal ions (especially ironions) in a reaction solvent, and ensuring that almost no amide impurity is contained in a reaction solution, so that product purity is increased effectively, yield is increased correspondingly, the practicality is high, and industrial application requirements are satisfied.